Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla®
PRINCETON, N.J. , May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ( FDA ) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined...
Toggle Summary Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
PRINCETON, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari , will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22,...
Toggle Summary Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting
PRINCETON, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla ® (AG200-15), an investigational, once weekly, low-dose hormonal contraceptive patch, will...
Toggle Summary Agile Therapeutics Reports First Quarter 2019 Financial Results
Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial...
Toggle Summary Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK
PRINCETON, N.J. , March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 at...
Toggle Summary Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress
PRINCETON, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation during the 2...
Toggle Summary Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial...
Toggle Summary Agile Therapeutics to Present at Upcoming Investor Conferences
PRINCETON, N.J. , March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tuesday March...
Toggle Summary Agile Therapeutics Announces $7.8 Million Private Placement
PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares...
Toggle Summary Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
Company now focused on completing plan to resubmit NDA in first half of 2019. PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced topline results from a comparative wear study testing the...
Shadow